Effects of high-intensity versus low-intensity praziquantel treatment on HIV disease progression and immunological responses among HIV and Schistosoma mansoni co-infected patients

Medical Research Council0 个研究点目标入组 363 人开始时间: 2017年2月1日最近更新: 2020年2月24日

适应症

试验速览

•1. ART-naïve HIV-positive men and women with evidence of co-infection with S. mansoni
•2. Aged 18 years or over
•3. Not eligible for ART (CD4 count more than 350 cells/mm3 or not in WHO Stage IV and advanced stage III)
•4. Willing to provide a stool sample for testing S. mansoni and other worms and accept treatment with praziquantel and albendazole
•5. Willing to provide blood for viral loads, CD4 count and other blood tests
•6. Able and willing to provide informed consent (literacy is not required)
•7. Willing to undergo HIV testing, counseling and receive HIV test results
•8. Available for follow-up for study duration
•9. Able and willing to provide adequate locator information for tracking purposes, and willing to be contacted by the study staff

•1. Pregnancy or planning to be pregnant during study period
•2. Has taken praziquantel in the preceding 3 months
•3. Symptomatic helminth infection (haemoglobin less than 8 g/dl, bloody diarrhea, clinically apparent liver disease)
•4. Symptomatic complications of S.mansoni (vomiting blood, hepatosplenomegaly)
•5. S. mansoni egg count more than 2000/g of stool as evidence points a high egg burden (>2000 eggs/g) highly associated with periportal fibrosis

发起方